[
  {
    "ts": null,
    "headline": "Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?",
    "summary": "Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future cancer treatment gains.",
    "url": "https://finnhub.io/api/news?id=fca0310c9ec21b09e39ec0df49e4f42da96d9936a969295f6cab3a75caca72c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755608880,
      "headline": "Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?",
      "id": 136430192,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future cancer treatment gains.",
      "url": "https://finnhub.io/api/news?id=fca0310c9ec21b09e39ec0df49e4f42da96d9936a969295f6cab3a75caca72c2"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know",
    "summary": "Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=cfd97278e15ffaf52970a92d8db20809f175088318277cb12e524ed9d66f5b04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755608402,
      "headline": "Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know",
      "id": 136430401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=cfd97278e15ffaf52970a92d8db20809f175088318277cb12e524ed9d66f5b04"
    }
  },
  {
    "ts": null,
    "headline": "Macquarie Healthcare Fund Q2 2025 Commentary",
    "summary": "For 2Q25, Macquarie Healthcare Fund Institutional Class shares outperformed the Fundâs benchmark, the Russell 3000 Healthcare Index.",
    "url": "https://finnhub.io/api/news?id=655eb96db3e0f03d6d68a1ad112eac29691c479b1a0d5c889fa859d753088728",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755581760,
      "headline": "Macquarie Healthcare Fund Q2 2025 Commentary",
      "id": 136416407,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2043764026/image_2043764026.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "For 2Q25, Macquarie Healthcare Fund Institutional Class shares outperformed the Fundâs benchmark, the Russell 3000 Healthcare Index.",
      "url": "https://finnhub.io/api/news?id=655eb96db3e0f03d6d68a1ad112eac29691c479b1a0d5c889fa859d753088728"
    }
  }
]